Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06070285
Other study ID # 72827906
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date October 2024
Est. completion date October 2026

Study information

Verified date September 2023
Source Power Life Sciences Inc.
Contact Michael B Gill
Phone 415-900-4227
Email bask@withpower.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Clinical trials, with a particular focus on recurrent ovarian cancer, play a crucial role in assessing the safety and efficacy of novel treatments for this condition. These trials serve as essential tools to determine whether new medications outperform traditional therapies, providing substantial evidence to support their widespread adoption. By actively participating in recurrent ovarian cancer observational study serves pivotal role in expanding the boundaries of medical knowledge and advancing the quality of care provided to those enduring the same condition.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 500
Est. completion date October 2026
Est. primary completion date October 2025
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Aged = 18 years old - Able to comprehend the investigational nature of the protocol and provide informed consent - Diagnosis of recurrent ovarian cancer Exclusion Criteria: - No diagnosis of recurrent ovarian cancer confirmed - Inability to perform regular electronic reporting - Patient does not understand, sign, and return consent form

Study Design


Locations

Country Name City State
United States Power Life Sciences San Francisco California

Sponsors (1)

Lead Sponsor Collaborator
Power Life Sciences Inc.

Country where clinical trial is conducted

United States, 

References & Publications (3)

Buechel M, Herzog TJ, Westin SN, Coleman RL, Monk BJ, Moore KN. Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option. Ann Oncol. 2019 May 1;30(5):721-732. doi: 10.1093/annonc/mdz104. — View Citation

Hilal Z, Schultheis B, Hartmann F, Dogan A, Cetin C, Krentel H, Schiermeier S, Tempfer CB. What Characterizes Long-term Survivors of Recurrent Ovarian Cancer? Case Report and Review of the Literature. Anticancer Res. 2016 Oct;36(10):5365-5371. doi: 10.21873/anticanres.11110. — View Citation

Ozga M, Aghajanian C, Myers-Virtue S, McDonnell G, Jhanwar S, Hichenberg S, Sulimanoff I. A systematic review of ovarian cancer and fear of recurrence. Palliat Support Care. 2015 Dec;13(6):1771-80. doi: 10.1017/S1478951515000127. Epub 2015 Mar 2. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Number of patients who decide to participate in a recurrent ovarian cancer clinical trial 3 months
Primary Rate of patients who remain in recurrent ovarian cancer clinical research to trial completion 12 months
See also
  Status Clinical Trial Phase
Completed NCT02195973 - Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer Phase 1
Not yet recruiting NCT05270720 - Dendritic Cell Vaccination With Standard Postoperative Chemotherapy for the Treatment of Adult Ovarian Cancer Phase 1
Completed NCT02303912 - Safety and Efficacy Study of Nuc-1031 and Carboplatin Combination to Treat Recurrent Ovarian Cancer Phase 1
Active, not recruiting NCT01802749 - Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer Phase 3
Completed NCT02788708 - Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer Phase 1
Recruiting NCT03564340 - Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers Phase 1/Phase 2
Recruiting NCT05610735 - Combination Therapy for Recurrent Ovarian Cancer Phase 1/Phase 2
Withdrawn NCT02083536 - LDFWART With Docetaxel in Patients With Platinum-Resistant Recurrent Ovarian Carcinoma Phase 1
Completed NCT03430518 - Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer Phase 1
Recruiting NCT03618706 - Standard of Care Therapy With Involved Field Radiation Therapy for Selective Recurrent Ovarian Cancer Phase 2
Recruiting NCT05311579 - Niraparib Plus Anlotinib for Recurrent Ovarian Cancer Phase 2
Active, not recruiting NCT01851746 - A Study of Docetaxel and Lobaplatin Versus Docetaxel and Carboplatin Combination Regimen in Patients With Platinum-sensitive (>6 Months) Relapsed Ovarian Cancer N/A
Active, not recruiting NCT06107868 - Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine Cancer Phase 1
Recruiting NCT06308406 - A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer Phase 1/Phase 2
Not yet recruiting NCT06365853 - A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression Phase 2
Completed NCT04718740 - A Drug-drug Interaction Study Of Fluzoparib (SHR3162) on Patients With Recurrent Ovarian Cancer Phase 1
Active, not recruiting NCT05335993 - A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer. Phase 2
Completed NCT01381861 - Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Phase 2
Not yet recruiting NCT05126342 - Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi Phase 2
Completed NCT02849353 - Combination of Cryosurgey and NK Immunotherapy for Recurrent Ovarian Cancer Phase 1/Phase 2